RecruitingPhase 4NCT07502560

A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland

A Randomized, Placebo Controlled, Observer-blind, Phase IV Pragmatic Trial to Evaluate the Effect of Recombinant Zoster Vaccine (Shingrix) on Incident Dementia Diagnosis in an Older Adult Population Aged ≥76 Years in Finland

Sponsor

GlaxoSmithKline

Enrollment

33,609 participants

Start Date

Mar 31, 2026

Study Type

INTERVENTIONAL

Conditions

Herpes Zoster

Summary

The purpose of this study is to evaluate the effect of the recombinant zoster vaccine on the risk of new diagnosis of dementia among adults aged 76 years or older in Finland. Participants will be enrolled and randomized in a 3:1 ratio to receive either recombinant zoster vaccine or placebo.

Eligibility

Min Age: 76 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo and a biological treatment called Recombinant zoster vaccine for people with herpes zoster. The study is currently recruiting participants at 8 locations. People eligible for this study include aged 76 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALRecombinant zoster vaccine

Recombinant zoster vaccine administered intramuscularly, one dose at Visit 1 (Day 1) and one dose at Visit 2 (between 2 and 6 months after the first dose), according to the approved recombinant zoster vaccine dosing schedule.

DRUGPlacebo

Placebo administered intramuscularly, one dose at Visit 1 (Day 1) and one dose at Visit 2 (between 2 and 6 months after the first dose).